Last reviewed · How we verify

NCT05309876

Secondary Prevention With the Lifestyle Tool

Recruiting now NA Last updated 16 July 2025
What this trial tests

NA trial testing Lifestyle tool in Cardiovascular Diseases in 11,000 participants. Currently enrolling.

Timeline
6 April 2022
Primary endpoint
31 December 2026
31 December 2028

Quick facts

Lead sponsorRegion Skane
PhaseNA
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposeprevention
Enrollment11,000
Start date6 April 2022
Primary completion31 December 2026
Estimated completion31 December 2028
Sites1 location across Sweden

Drugs / interventions tested

Conditions studied

Sponsor

Region Skane — full company profile →

Who can join

Adults 35 to 80, any sex, with Cardiovascular Diseases. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In this study participants will be randomized to use a digital lifestyle tool over three years or to a control group without access to the tool. The investigators will prospectively follow the incidence of major cardiovascular events in patients who have previously suffered from a myocardial infarction in those using the tool regularly and those in the control group.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Lifestyle tool

Trials testing the same drug.

Other recruiting trials for Cardiovascular Diseases

Currently open trials in the same condition.

Other Region Skane trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05309876.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing